Topic: budget

moneyroll

The top 10 pharma R&D budgets in 2016

Last year, biopharma won its share of new drug approvals as R&D spending came to fruition, but drugmakers also suffered a number of setbacks, cut research staff, rejigged their operations and refocused their pipelines.

10. GlaxoSmithKline

GlaxoSmithKline has one of the lowest R&D budgets in percentage of revenue terms of its peers; although its research budget was slightly up on 2015, this is still markedly down from the around £4 billion it was spending in 2012-13.
Bristol-Myers

9. Bristol-Myers Squibb

Bristol-Myers Squibb has long been highly regarded when it comes to its R&D—a small Big Pharma with a biotech bent, it has always funneled much money into its research budget.
Eli Lilly headquarters

8. Eli Lilly

Eli Lilly spent nearly a quarter of its income on R&D last year, putting it near the top of its peers in percentage terms, and saw some of that spend pay off—overall, however, last year was a mixed bag for the company’s research.
Sanofi

7. Sanofi

Sanofi had a bit of a year to forget when it came to buying up biotechs and expanding its pipeline—it failed to beat out Pfizer in its winning $14 billion bid for cancer biotech Medivation, losing out on some increasingly hot cancer candidates and blockbuster prostate cancer med Xtandi.